Dr. Rowinsky has served as the chairman of Kitov’s board of directors since 2019. Dr. Rowinsky has been the Executive Director and President of RGenix, Inc. since June 2016, and has served as Chief Scientific Officer of Clearpath Development Co. since June 2016. Prior to that, Dr. Rowinsky served as the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics, Inc. from 2011 to 2016. In 2010, Dr. Rowinsky co-founded Primrose Therapeutics and then became its CEO until it was acquired in 2011. He served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies that was acquired by Eli Lilly and Company, from 2005 to 2010. Before that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. He also served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Rowinsky is on the boards of directors of public companies Biogen Idec, Inc., Fortress Biosciences, Inc., and Verastem Inc. He formerly served on the boards of directors of public companies Navidea Biopharmaceuticals Inc. (2010-2018), BIND Therapeutics (2014-2016), and Biophytis S.A. (2018-2019), as well as at a number of privately-held companies. Dr. Rowinsky holds a BA in Liberal Arts from New York University and an MD from the Vanderbilt University School of Medicine. He completed a residency in internal medicine at the University of California and a fellowship in medical oncology at Johns Hopkins University. Dr. Rowinsky led the clinical development and regulatory approval of several oncology therapies including Erbitux (cetuximab).
Isaac Israel
Isaac Israel has served as Kitov’s CEO and a member of the board since 2012. Prior to joining Kitov, Mr. Israel founded BeeContact (formerly TASE: BCNT) and served as CEO from 2001 to 2007. Mr. Israel has served as owner and founding CEO of Uneri Capital, a capital market consulting firm specializing in healthcare, since 2008. He serves on the board of various public and private healthcare corporations, including chairman of the board of NextGen Biomed, which is traded on the TASE.
Simcha Rock – CPA, MBA
Simcha Rock has served as a member of the board since 2013. He was Kitov’s CFO from 2013 to 2018, at which time he retired from the position. Mr. Rock was a Private Equity Manager at Edmond de Rothschild Private Equity Management, a firm specializing in the management of venture capital and other private equity investments funds, from 2000 to 2011. In that capacity, he was responsible for all financial, legal, and administrative matters for several investment funds. Prior to that, Mr. Rock held financial management positions at Intel Electronics, The Jerusalem College of Technology, and JC Technologies. Mr. Rock holds a BA from Yeshiva University and an MBA from Cleveland State University.
Ido Agmon - MBA
Ido Agmon has served as a member of Kitov’s board since 2016. Mr. Agmon is a Manager of Aviv New-Tech, a private investment fund that manages a portfolio of publicly-traded Israeli and global biomed and technology companies. He also serves as an independent consultant, providing startups and technology-based ventures with strategic planning and fundraising advice. Previously, he served as the CEO of the Meytav Technology Incubator, an Israeli-based accelerator for biotech, pharma, and medtech ventures with over 20 portfolio companies. Mr. Agmon has also served on the board of a number of biomed ventures. He was the Director of Business Development at the ATI incubator, a technology incubator specializing in biomed and cleantech projects, where he was responsible for deal flow and project evaluation. Mr. Agmon holds a BA in Business Administration and Life Sciences from Tel Aviv University and an MBA from The Hebrew University of Jerusalem.
Steven Steinberg - CPA
Steven Steinberg has served as a member of Kitov’s board since 2016. Mr. Steinberg serves as the Chief Financial Officer of Glide Talk, a technology company in the video messaging arena. Previously, he served as Vice President, Finance at ClientConnect, a subsidiary of Conduit. Mr. Steinberg has provided startups and mature organizations with advice in financial reporting, due diligence, and business models. He also served as CFO of Answers Corporation, a NASDAQ-listed company. He has held a number of finance and CFO roles following a 10-year stint as an Audit Manager at Coopers & Lybrand (currently Price Waterhouse Coopers) in New York. Mr. Steinberg holds a BA in Business Administration from Florida International University – School of Business Administration and received his CPA license from the state of New York.
Revital Stern-Raf - CPA, MBA
Revital Stern-Raf has served as a member of Kitov’s board since 2017. Ms. Stern-Raff has served as the Chief Financial Officer of several municipal development and community association units of Givatayim, Israel, since 2013. Ms. Stern-Raff held comptroller and economist positions at Ilex Medical (TASE: ILX), a publicly-traded medical diagnostic equipment company, between 2006 and 2013. Prior to that, she held a number of comptroller and public accounting positions. Ms. Stern-Raff was an independent director at Real Imaging Holdings (TASE: RIMG), a publicly-traded breast cancer diagnostics company, between 2009 and 2012. She holds an MBA in Finance and a BA in Business Administration – Information Technology and Finance from the Rishon Letzion College of Management in Israel, and is a licensed CPA in Israel.
Ran Tzror - CPA, MBA
Ran Tzror has served as a member of Kitov’s board since 2017. Mr. Tzror has been the Director of S.Y. Glilot, a real-estate company, since 2014. Prior to that, he held several roles in corporate business development and at the office of the CEO & President, and was Director of the Corporate Post Merger Integration Office at Teva Pharmaceutical Industries between 2010 and 2014. He served as a Senior Associate at Somekh Chaikin Certified Public Accountants (Israel), a member firm of KPMG International, between 2007 and 2010. He started his career as a legal intern at the commercial division of Yigal Arnon & Co., Advocates & Notary from 2006 to 2007. Mr. Tzror holds a BA in Accounting, LLB in Law and an MBA in Financial Management from Tel Aviv University. He also completed courses at the Kellogg Graduate School of Management at Northwestern University. Mr. Tzror is a licensed CPA in Israel, and was admitted to the Israeli Bar Association.
